All In Biotech

Drug Trial Radar · NCT07498634

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active Ankylosing Spondylitis (AS)

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Sep 21, 2023

Primary completion

Aug 1, 2025

Study completion Nov 14, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study. Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.

Conditions

  • Phase III

Interventions

  • XKH004Drug

    Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Is ASAS 40 achieved at W16?Time frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Changzheng Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.